| REVIEW ARTICLE |
|
| Year : 2020 | Volume
: 11
| Issue : 3 | Page : 131-136 |
|
|
Dipeptidyl-peptidase-4 inhibitors in type 2 diabetes and COVID-19: From a potential repurposed agent to a useful treatment option
Awadhesh Kumar Singh1, Ritu Singh2
1 Department of Diabetes & Endocrinology, G.D Hospital and Diabetes Institute, Kolkata, India
2 Department of Gynecology & Obstetrics, G.D Hospital and Diabetes Institute, Kolkata, India
Correspondence Address:
Dr. Awadhesh Kumar Singh
Department of Diabetes & Endocrinology, GD Hospital and Diabetes Institute, Kolkata, West Bengal.
India
 Source of Support: None, Conflict of Interest: None  | 3 |
DOI: 10.4103/JOD.JOD_53_20
|
|
|
Dipeptidyl-peptidase-4 inhibitors (DPP-4Is) are very commonly prescribed antidiabetic agents in the treatment of type 2 diabetes owing to its modest ability to reduce blood glucose without ensuing any hypoglycemia and weight gain. Many experts have advised continuing DPP-4Is in patient with type 2 diabetes with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease 2019 (COVID-19). In addition, several researchers have proposed DPP-4Is to be used as a repurposed agent for COVID-19 not only for the patients with diabetes but also for those without diabetes. We aimed to review as to what could be the reason behind this approach and how does the use of DPP-4Is alter the outcome in patients with type 2 diabetes and COVID-19. |
|
|
|
| [FULL TEXT] [PDF]* |
|
 |
|
